RxDoctor Payments DataLook up a doctor →

John Marino, MD

Child & Adolescent Psychiatry · Canandaigua, NYNPI 1831105899

Payments from drug & device makers

$69,509in general payments, 2019–2025

Across 1,194 payments — averaging $58.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43K
  • Idorsia Pharmaceuticals US Inc$6K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
  • Alkermes, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • plus $11K from 27 others

What the payments were for

  • Speaking & faculty fees$42,13861%
  • Travel & lodging$1,3132%
  • Food & beverage$25,63537%
  • Education$4231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,509 in reported general payments places this provider in the 95th percentile of 317 child & adolescent psychiatry providers in New York.

See all child & adolescent psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$12,621
Medicare patients
18
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$130,351
AristadaAripiprazole Lauroxil30$90,688
Austedo XrDeutetrabenazine12$58,873
VraylarCariprazine Hcl23$31,159
BelsomraSuvorexant11$4,546
Aripiprazole41$3,770
Bupropion XlBupropion Hcl79$2,111
Duloxetine Hcl64$943
Carbamazepine13$540
Alprazolam77$479
Temazepam30$434
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$424
Lurasidone Hcl13$390
Clonazepam52$383
Quetiapine Fumarate21$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,024$130,35116 claims
Alkermes, Inc.Aristada$2,417$90,68830 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$1,811$58,87312 claims
AbbVieVraylar$42,843$31,15923 claims
MerckBelsomra$45$4,54611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 child & adolescent psychiatry providers in New York.

Other child & adolescent psychiatry in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →